DEF 14A: Alkermes Seeks Shareholder Approval for Director Elections, Executive Pay, and Stock Incentive Plan Amendments

Alkermes is holding its 2024 Annual General Meeting on May 31, 2024, to vote on director elections, executive compensation, auditor ratification, and amendments to the stock option and incentive plan.

Summary

• Alkermes plc is holding its 2024 Annual General Meeting of Shareholders on May 31, 2024, in Dublin, Ireland.
• Shareholders as of March 18, 2024, are entitled to vote on several proposals.
• The proposals include the election of 11 director nominees, an advisory vote on executive compensation, and a vote on the frequency of future advisory votes on executive compensation.
• Shareholders will also vote to ratify the appointment of PricewaterhouseCoopers LLP as the independent auditor and accounting firm and to authorize the Audit and Risk Committee to set the auditor's remuneration.
• Additionally, shareholders will vote on approving amendments to the Alkermes plc 2018 Stock Option and Incentive Plan, renewing Board authority to allot and issue shares under Irish law, and renewing Board authority to disapply statutory pre-emption rights under Irish law.
• The Board of Directors recommends voting in favor of all proposals.

Sentiment

Score: 8

Explanation: The document presents a positive outlook for Alkermes, highlighting strong financial performance, strategic achievements, and a commitment to corporate responsibility and governance. The tone is optimistic and confident, reflecting a well-managed and successful company.

Positives

• Alkermes achieved significant commercial and scientific successes in 2023.
• The company is focused on strong corporate governance and ethical operations.
• Alkermes is committed to diversity, inclusion, and belonging initiatives.
• The company has a strong and scalable commercial infrastructure focused on serious mental illness and addiction.
• Alkermes has proven development capabilities with an advancing neuroscience pipeline.
• The company has an efficient operating structure and capital allocation strategy that positions the business for sustained profitability, cash generation, and growth.
• The company has a dedicated and skilled employee base committed to excellence in their work.
• The Board has added eight new, independent directors in the last five years, enhancing diversity and expertise.
• The company has an active shareholder engagement program with independent director participation.
• The company has a clawback policy and recoupment policy in respect of certain equity and cash compensation.

Risks

• The document mentions risks related to business strategy and execution, including the recently completed separation of the oncology business.
• The document mentions risks related to operational efficiency, optimization of the Company's cost structure and enhanced profitability.
• The document mentions risks related to environmental, health, safety and security programs.
• The document mentions risks related to cybersecurity, information technology and data privacy.
• The document mentions risks related to environmental stewardship and sustainability matters, including climate change.

Future Outlook

Alkermes remains committed to the pursuit of great science that can make a real impact for patients and their families and is positioned for sustained profitability, cash generation and growth.

Management Comments

• Richard F. Pops, CEO and Chairman: 'Alkermes entered 2024 as a stand-alone neuroscience company in a position of strength.'
• Richard F. Pops, CEO and Chairman: 'We remain committed to the pursuit of great science that can make a real impact for patients and their families.'
• Frank A. Wilson, Lead Independent Director: '2023 was a remarkably productive year for the Company and a busy year for the Board.'
• Frank A. Wilson, Lead Independent Director: 'The Board considers this input essential in its ongoing commitment to excellence in the execution of its strategic oversight and corporate governance responsibilities and is committed to continuing such engagement in the future.'

Industry Context

The announcement reflects Alkermes' strategic shift towards neuroscience and its efforts to streamline operations and enhance profitability, aligning with broader industry trends of focusing on core therapeutic areas and improving efficiency.

Comparison to Industry Standards

• Alkermes' executive compensation practices are benchmarked against a peer group of biopharmaceutical companies.
• The company aims to align its compensation with the 50th percentile of its peer group.
• The company's corporate governance practices are regularly reviewed and refined based on market best practices and shareholder feedback.
• The company's commitment to ESG and DIB initiatives aligns with growing industry expectations for corporate responsibility.

Stakeholder Impact

• Shareholders will be impacted by the decisions made at the Annual General Meeting.
• Employees will be impacted by the company's compensation and benefits programs.
• Patients will be impacted by the company's focus on developing and commercializing new medicines.
• The local communities where Alkermes operates will be impacted by the company's corporate responsibility and sustainability initiatives.

Next Steps

• Shareholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will hold its Annual General Meeting on May 31, 2024.
• The company will continue to engage with shareholders and other stakeholders on a regular basis.

Key Dates

Keywords

Alkermes, shareholders, compensation, directors, executive, Board, governance, incentive, shares, equity, meeting, Irish